OncoSil Medical Ltd. (ASX: OSL) is a global medical device company that focuses on interventional oncology, with the mission to improve the outcomes for people living with cancer by utilising selective and targeted intratumoral placement of Phosphorous 32 (32P) Microparticles. The Oncosil device focuses on using localised radiation therapy for the treatment of pancreatic cancer. Oncosil is subject to a great deal of risk as its control trials are complicated to implement and expensive to design while subject to rigorous regulatory requirements. Despite this, Oncosil (ASX: OSL) has expanded to a total of 38 countries and it's being used to treat patients in Spain and Israel to make a few. 

Early Achievements of OncoSil

• The device has already received breakthrough device designation in the European Union, United Kingdom, and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.
•  OncoSil is commercialising this it’s medical technology and is currently approved for sale in 30+ countries including the European Union, United Kingdom, Turkey, and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy, and Israel.

Biotech Stocks Perform Well in the Long Run

The development/commercialisation of Biotech products and treatments is subject to extensive laws and regulations. Furthermore, human clinical trials are costly and difficult to design and implement, partly because they are subject to rigorous regulatory requirements. This is why biotech stocks tend to underperform in their early years, before gaining a more stable footing once their products are increasingly used and adopted by clinics and patients. Although biotech stocks are very risky, they are equally the 

For example, in 2015, several biotech stocks such as Regeneron Pharmaceuticals (REGN), Kite Pharma (KITE), and Gilead Sciences (GILD) were down by 30% and since then, some of these stocks have recovered by over 65% cumulatively. For stocks such as Regeneron Pharmaceuticals (REGN), it took twenty years for their share price to increase from $26 to $240 per share i.e. between 2010 - 2020. Over twenty years were spent improving their treatments and trying to reach new customers. Ultimately, these stocks have performed well and come off them have seen their share price rise by over 180% in the last decade. 

Meanwhile, other innovative stocks such as Actinogen Medical Ltd (ASX: ACW) recently found support at the lower line of a falling wedge pattern. If it breaks above the upper line, the target potential is very high, but its current performance is only a buy opportunity for investors looking to grow their portfolios over the long run. 

There are quite a few other small biotechnology names with promising prospects that appear mispriced and could stay that way for a while, OncoSil (ASX: OSL). However, it is important to note that analysts now expect Oncosil (ASX: OSL) to gain in the medium term, but its share price will not improve due to sentiment. The quality of its innovative treatment will ultimately make it worth the wait for investors who stick to the stock. 

Positive signals are currently not priced in

Furthermore, there are loads of positive signals that are currently not fully priced in, including its inclusion in several insurers' lists (BUPA and Imperial NHS Trust) and its special designation from the FDA. This is why Oncosil (ASX: OSL) is grossly mispriced and can stay that way for the medium term. However, improved technical action and use will cause the share price to recover over the medium term on a more sustained basis.

Oversold Positions are a Strong Buy Opportunity

It appears that many inexperienced investors and traders have exited Oncosil, interpreting it as a breakdown in a downtrend flag. Fundamentally, nothing has altered significantly to warrant such steep declines in valuation. This biotech opportunity is currently trading at levels often considered as stop-loss thresholds. Holding Oncosil (ASX: OSL) could generate long-term returns. 

Monitoring Oncosil (ASX: OSL) on the monthly chart reveals a promising RSI signal, indicating a potential sharp rebound shortly. While volumes have dried up and the share price has reacted, we can expect a recovery soon as the suspension of trading equally accentuated this trend. However, when trading begins in full swing, the price will likely recover once more, boosting near-term returns for stockholders via a price increase.